Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Excell Research

Neither a doctor nor a teaching hospital

Research payments

$3,922,205

481 payments

Through program year 2025, Excell Research is reported as receiving $3,922,205 in research payments, across 481 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $252,770 15
2024 Research $181,754 6
2023 Research $46,949 3
2022 Research $693,487 84
2021 Research $1,151,832 135
2020 Research $989,165 156
2019 Research $606,248 82

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $1,695,318 250 payments
  2. Sage Therapeutics, Inc. $906,137 100 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $555,923 14 payments
  4. E.R. Squibb & Sons, L.L.C. $351,297 8 payments
  5. H. Lundbeck A S $213,953 22 payments
  6. Jazz Pharmaceuticals Inc. $116,730 11 payments
  7. AbbVie, Inc. $43,537 12 payments
  8. Corcept Therapeutics $24,177 10 payments
  9. GW Research Limited $12,590 2 payments
  10. Sunovion Pharmaceuticals Inc. $2,494 51 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $370,043 16 payments
  2. A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $364,333 18 payments
  3. A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder $246,352 19 payments
  4. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $232,765 36 payments
  5. A Study to Evaluate the Efficacy and Safety of Sage-217 in Participants With Severe Postpartum Depression (PPD) $194,834 24 payments
  6. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $177,721 3 payments
  7. An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $160,049 2 payments
  8. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $139,980 23 payments
  9. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $131,756 22 payments
  10. A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder $118,959 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record